NFL Biosciences SA (ALNFL.PA)
EUR 1.63
(-1.81%)
EUR 1.63
(-1.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.37 Million EUR | 553.91% |
| 2022 | 668.95 Thousand EUR | 13.62% |
| 2021 | 588.76 Thousand EUR | 296.02% |
| 2020 | 148.67 Thousand EUR | 59.14% |
| 2019 | 93.42 Thousand EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 870.15 Thousand EUR | -54.82% |
| 2023 FY | 4.37 Million EUR | 553.91% |
| 2023 Q4 | 1.92 Million EUR | -21.34% |
| 2023 Q2 | 2.44 Million EUR | 42.98% |
| 2022 Q4 | 1.71 Million EUR | 37.14% |
| 2022 FY | 668.95 Thousand EUR | 13.62% |
| 2022 Q2 | 1.24 Million EUR | 0.0% |
| 2021 FY | 588.76 Thousand EUR | 296.02% |
| 2021 Q2 | 200.47 Thousand EUR | 0.0% |
| 2020 FY | 148.67 Thousand EUR | 59.14% |
| 2019 FY | 93.42 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -4.725% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 96.566% |
| Adocia SA | 15.62 Million EUR | 72.011% |
| Aelis Farma SA | 18.81 Million EUR | 76.756% |
| Biophytis S.A. | 14.33 Million EUR | 69.481% |
| Advicenne S.A. | 8.21 Million EUR | 46.752% |
| genOway Société anonyme | 16.73 Million EUR | 73.866% |
| IntegraGen SA | 5.35 Million EUR | 18.275% |
| Medesis Pharma S.A. | 1.56 Million EUR | -179.588% |
| Neovacs S.A. | 10.34 Million EUR | 57.709% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -58.213% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -154.624% |
| Sensorion SA | 27.05 Million EUR | 83.831% |
| Theranexus Société Anonyme | 3 Million EUR | -45.57% |
| TME Pharma N.V. | 5.49 Million EUR | 20.423% |
| Valbiotis SA | 9.86 Million EUR | 55.676% |
| TheraVet SA | 1.64 Million EUR | -166.029% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 78.473% |
| argenx SE | 1.34 Billion EUR | 99.674% |
| BioSenic S.A. | 7.58 Million EUR | 42.314% |
| Celyad Oncology SA | 8.49 Million EUR | 48.476% |
| DBV Technologies S.A. | 89.4 Million EUR | 95.107% |
| Galapagos NV | 327.98 Million EUR | 98.666% |
| Genfit S.A. | 54.8 Million EUR | 92.018% |
| GeNeuro SA | 14.35 Million EUR | 69.532% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | 75.68% |
| Innate Pharma S.A. | 64.57 Million EUR | 93.225% |
| Inventiva S.A. | 120.18 Million EUR | 96.36% |
| MaaT Pharma SA | 21.59 Million EUR | 79.746% |
| MedinCell S.A. | 32.92 Million EUR | 86.713% |
| Nanobiotix S.A. | 58.92 Million EUR | 92.577% |
| Onward Medical N.V. | 20.64 Million EUR | 78.812% |
| Oryzon Genomics S.A. | 18.49 Million EUR | 76.351% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 81.456% |
| Oxurion NV | 12.21 Million EUR | 64.186% |
| Pharming Group N.V. | 204.24 Million EUR | 97.858% |
| Poxel S.A. | 28.76 Million EUR | 84.793% |
| GenSight Biologics S.A. | 32.66 Million EUR | 86.606% |
| Transgene SA | 31.23 Million EUR | 85.994% |
| Financière de Tubize SA | 114.38 Thousand EUR | -3724.103% |
| UCB SA | 2.94 Billion EUR | 99.851% |
| Valneva SE | 134.92 Million EUR | 96.758% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 82.284% |